The trademark application LUMAKRAS was filed by Amgen Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on December 3, 2020, and it was registered by office on March 12, 2021 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations for use in the prevention of amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders
Pharmaceutical preparations for use in the treatment of amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders
Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amylodiosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders.